<!DOCTYPE html>
<html lang="" xml:lang="">
  <head>
    <title>  COVID-19 vaccine trials:</title>
    <meta charset="utf-8" />
    <meta name="author" content="Nima Hejazi   University of California, Berkeley  Division of Biostatistics, School of Public Health" />
    
    
    
    
    
    <link rel="stylesheet" href="xaringan-themer.css" type="text/css" />
  </head>
  <body>
    <textarea id="source">
class: center, middle, inverse, title-slide

# <svg viewBox="0 0 512 512" style="height:1em;position:relative;display:inline-block;top:.1em;fill:white;" xmlns="http://www.w3.org/2000/svg"> <path d="M201.5 174.8l55.7 55.8c3.1 3.1 3.1 8.2 0 11.3l-11.3 11.3c-3.1 3.1-8.2 3.1-11.3 0l-55.7-55.8-45.3 45.3 55.8 55.8c3.1 3.1 3.1 8.2 0 11.3l-11.3 11.3c-3.1 3.1-8.2 3.1-11.3 0L111 265.2l-26.4 26.4c-17.3 17.3-25.6 41.1-23 65.4l7.1 63.6L2.3 487c-3.1 3.1-3.1 8.2 0 11.3l11.3 11.3c3.1 3.1 8.2 3.1 11.3 0l66.3-66.3 63.6 7.1c23.9 2.6 47.9-5.4 65.4-23l181.9-181.9-135.7-135.7-64.9 65zm308.2-93.3L430.5 2.3c-3.1-3.1-8.2-3.1-11.3 0l-11.3 11.3c-3.1 3.1-3.1 8.2 0 11.3l28.3 28.3-45.3 45.3-56.6-56.6-17-17c-3.1-3.1-8.2-3.1-11.3 0l-33.9 33.9c-3.1 3.1-3.1 8.2 0 11.3l17 17L424.8 223l17 17c3.1 3.1 8.2 3.1 11.3 0l33.9-34c3.1-3.1 3.1-8.2 0-11.3l-73.5-73.5 45.3-45.3 28.3 28.3c3.1 3.1 8.2 3.1 11.3 0l11.3-11.3c3.1-3.2 3.1-8.2 0-11.4z"></path></svg> COVID-19 vaccine trials:
## Evaluating <em>causal</em> vaccine efficacy
### Nima Hejazi<br> <span style="font-size: 75%;"> University of California, Berkeley<br> Division of Biostatistics, School of Public Health </span>
### <svg viewBox="0 0 512 512" style="height:1em;position:relative;display:inline-block;top:.1em;fill:white;" xmlns="http://www.w3.org/2000/svg"> <path d="M459.37 151.716c.325 4.548.325 9.097.325 13.645 0 138.72-105.583 298.558-298.558 298.558-59.452 0-114.68-17.219-161.137-47.106 8.447.974 16.568 1.299 25.34 1.299 49.055 0 94.213-16.568 130.274-44.832-46.132-.975-84.792-31.188-98.112-72.772 6.498.974 12.995 1.624 19.818 1.624 9.421 0 18.843-1.3 27.614-3.573-48.081-9.747-84.143-51.98-84.143-102.985v-1.299c13.969 7.797 30.214 12.67 47.431 13.319-28.264-18.843-46.781-51.005-46.781-87.391 0-19.492 5.197-37.36 14.294-52.954 51.655 63.675 129.3 105.258 216.365 109.807-1.624-7.797-2.599-15.918-2.599-24.04 0-57.828 46.782-104.934 104.934-104.934 30.213 0 57.502 12.67 76.67 33.137 23.715-4.548 46.456-13.32 66.599-25.34-7.798 24.366-24.366 44.833-46.132 57.827 21.117-2.273 41.584-8.122 60.426-16.243-14.292 20.791-32.161 39.308-52.628 54.253z"></path></svg> <a href = "https://twitter.com/nshejazi" style = "color: white;"><span class="citation">@nshejazi</span></a> <br> <svg viewBox="0 0 512 512" style="height:1em;position:relative;display:inline-block;top:.1em;fill:white;" xmlns="http://www.w3.org/2000/svg"> <path d="M326.612 185.391c59.747 59.809 58.927 155.698.36 214.59-.11.12-.24.25-.36.37l-67.2 67.2c-59.27 59.27-155.699 59.262-214.96 0-59.27-59.26-59.27-155.7 0-214.96l37.106-37.106c9.84-9.84 26.786-3.3 27.294 10.606.648 17.722 3.826 35.527 9.69 52.721 1.986 5.822.567 12.262-3.783 16.612l-13.087 13.087c-28.026 28.026-28.905 73.66-1.155 101.96 28.024 28.579 74.086 28.749 102.325.51l67.2-67.19c28.191-28.191 28.073-73.757 0-101.83-3.701-3.694-7.429-6.564-10.341-8.569a16.037 16.037 0 0 1-6.947-12.606c-.396-10.567 3.348-21.456 11.698-29.806l21.054-21.055c5.521-5.521 14.182-6.199 20.584-1.731a152.482 152.482 0 0 1 20.522 17.197zM467.547 44.449c-59.261-59.262-155.69-59.27-214.96 0l-67.2 67.2c-.12.12-.25.25-.36.37-58.566 58.892-59.387 154.781.36 214.59a152.454 152.454 0 0 0 20.521 17.196c6.402 4.468 15.064 3.789 20.584-1.731l21.054-21.055c8.35-8.35 12.094-19.239 11.698-29.806a16.037 16.037 0 0 0-6.947-12.606c-2.912-2.005-6.64-4.875-10.341-8.569-28.073-28.073-28.191-73.639 0-101.83l67.2-67.19c28.239-28.239 74.3-28.069 102.325.51 27.75 28.3 26.872 73.934-1.155 101.96l-13.087 13.087c-4.35 4.35-5.769 10.79-3.783 16.612 5.864 17.194 9.042 34.999 9.69 52.721.509 13.906 17.454 20.446 27.294 10.606l37.106-37.106c59.271-59.259 59.271-155.699.001-214.959z"></path></svg> <a href="https://nimahejazi.org" style="color: white;">nimahejazi.org</a> <br>

---



class: inverse, center, middle

.huge[Vaccine correlates]



&lt;style type="text/css"&gt;
.remark-slide-content {
    font-size: 22px
}
&lt;/style&gt;

---

## Correlates of risk and protection

Two, interrelated goals of vaccine correlates analyses are to

* identify/validate possible __surrogate endpoints__\*;
* understand __protective mechanisms__ of vaccines.

If an __immune correlate__ is established to __reliably predict vaccine
efficacy__, then subsequent efficacy trials may use it as the __primary
endpoint__.

__Accelerates approval__ of

* existing vaccines in __different populations__ (e.g., in children);
* __new vaccines__ within the same class.

.footnote[[*] [Prentice (1989)](https://doi.org/10.1002/sim.4780080407) ]

---

## Correlates of risk and protection

.large[__Two levels of correlates analysis__\*:]

__Correlates of risk (CoR):__

* Correlation of immune response in vaccine recipients with outcome
* Prediction of risk
* Evaluated via _associative_ parameters

__Correlates of protection (CoP)__:

* Evaluate immune response's ability to predict vaccine efficacy
* Evaluated via _causal_ parameters

.footnote[[*] [Plotkin and Gilbert (2012)](https://doi.org/10.1093/cid/cis238),
[Qin et al. (2007)](https://doi.org/10.1086/522428) ]

---

## Correlates of protection

__Effect modifiers of vaccine efficacy (VE)__

* How does VE vary across subgroups defined by immune response?
* e.g., [Juraska et al. (2020)](https://doi.org/10.1093/biostatistics/kxy074)


__Path-specific mediators of VE__

* What percentage of VE is attributable to immune response?
* [Cowling et al. (2019)](https://doi.org/10.1093/cid/ciy759)
* [Benkeser et al. (2021+)](https://arxiv.org/abs/2103.02643)

__Stochastic interventional VE__

* How would shifting the immune response distribution impact VE?
* [Hejazi et al. (2020)](https://doi.org/10.1111/biom.13375), Hejazi et al.
  (2021+)

---

## Measuring correlates

* Running assays on &gt;30k samples is .red[expensive], __statistically
  unnecessary__.
* Use a __case-cohort design\*__ to _measure immune responses_ in
  * a stratified random subcohort (\~1600 individuals)
  * all SARS-CoV-2 infection endpoints

&lt;img src="/home/nsh/git/conf_ser2021_txshift_covpn/slides_rmd/img/casecohort.png" width="70%" style="display: block; margin: auto;" /&gt;

.footnote[[*] [Prentice (1986)](https://www.jstor.org/stable/2336266) ]

---

## Measuring correlates

* Case-cohort designs are a special case of _two-phase sampling\*_:
  * Phase 1: measure baseline, vaccine, endpoint on everyone.
  * Phase 2: given baseline, vaccine, endpoint, select members of immune
    response subcohort with (possibly known) probability.

--

* Complete (.red[unobserved]) data `\(X = (L, A, S, Y) \sim P_0^X \in \mathcal{M}^X\)`:
  * `\(L\)` (covariates): sex, age, baseline risk/exposure score,
  * `\(A\)` (treatment): randomized placebo vs. vaccine assignment,
  * `\(S\)` (exposure): candidate marker immune response profiles at Day 57,
  * `\(Y\)` (outcome): SARS-CoV-2 infection (starting at 7 days after Day 57).
* Observed data `\(O = (C, C X) = (L, C, C S, Y)\)`, where `\(C \in \{0,1\}\)` indicates
  inclusion in the second phase sample.

.footnote[[*] [Breslow et al. (2003)](https://doi.org/10.1214/aos/1059655907),
[Breslow et al. (2009)](https://doi.org/10.1007/s12561-009-9001-6) ]

---

## Statistical challenges

__Estimation in two-phase designs:__

* Individuals who contract COVID may __differ from other participants__.
* Two-phase design .blue[_over-samples_] these individuals.
* Augmented inverse weighting methods __account for differences__.

--

__CoVPN statisticians are committed to open science:__

* A version-controlled SAP is
  [available](https://doi.org/10.6084/m9.figshare.13198595) for review.
* An [open source GitHub
  repository](https://github.com/CoVPN/correlates_reporting) implements methods
  from the SAP.
  - Tools: `RMarkdown`, `renv`, `bookdown`, GNU Make, Travis-CI, AWS.
  * Proof-of-concept for validating (causal) ML in regulatory context.

???

__Low case numbers due to highly effective vaccines (e.g., 95% VE):__

* Power for CoP analyses driven by __vaccine breakthroughs__.
* CoR `\(&gt;\)` 25 breakthroughs; CoP `\(&gt;\)` 50 breakthroughs.

---

class: inverse, center, middle

.huge[Stochastic Interventional Vaccine Efficacy (SVE) &lt;svg viewBox="0 0 512 512" style="height:1em;position:relative;display:inline-block;top:.1em;fill:white;" xmlns="http://www.w3.org/2000/svg"&gt;  &lt;path d="M201.5 174.8l55.7 55.8c3.1 3.1 3.1 8.2 0 11.3l-11.3 11.3c-3.1 3.1-8.2 3.1-11.3 0l-55.7-55.8-45.3 45.3 55.8 55.8c3.1 3.1 3.1 8.2 0 11.3l-11.3 11.3c-3.1 3.1-8.2 3.1-11.3 0L111 265.2l-26.4 26.4c-17.3 17.3-25.6 41.1-23 65.4l7.1 63.6L2.3 487c-3.1 3.1-3.1 8.2 0 11.3l11.3 11.3c3.1 3.1 8.2 3.1 11.3 0l66.3-66.3 63.6 7.1c23.9 2.6 47.9-5.4 65.4-23l181.9-181.9-135.7-135.7-64.9 65zm308.2-93.3L430.5 2.3c-3.1-3.1-8.2-3.1-11.3 0l-11.3 11.3c-3.1 3.1-3.1 8.2 0 11.3l28.3 28.3-45.3 45.3-56.6-56.6-17-17c-3.1-3.1-8.2-3.1-11.3 0l-33.9 33.9c-3.1 3.1-3.1 8.2 0 11.3l17 17L424.8 223l17 17c3.1 3.1 8.2 3.1 11.3 0l33.9-34c3.1-3.1 3.1-8.2 0-11.3l-73.5-73.5 45.3-45.3 28.3 28.3c3.1 3.1 8.2 3.1 11.3 0l11.3-11.3c3.1-3.2 3.1-8.2 0-11.4z"&gt;&lt;/path&gt;&lt;/svg&gt;]

---

## Exposure-Shifting Interventions

![](./img/shift_animation.gif)

---

## Stochastic Interventions

__Target Causal Parameter:__

* _Stochastic interventions\*_ as modified exposure policies:
  `$$d(s,l) = s + \delta,$$`
  where `\(\delta := 0\)` if `\(s + \delta\)` is .red[not] plausible for a given
  individual.
* Our estimand is `\(\psi_{0, d} := \mathbb{E}_{P_0^d}\{Y_{d(S,L)}\}\)`,
  mean of counterfactual `\(Y_{d(S, L)}\)`.

--

__Efficient Estimation:__

* _Doubly robust_ one-step and targeted minimum loss (TML) estimators rooted in
  semiparametric efficiency theory.
* Allow state-of-the-art ML for flexible nuisance parameter estimation.

.footnote[[*] [Díaz &amp; van der Laan
  (2012)]( https://doi.org/10.1111/j.1541-0420.2011.01685.x), [Díaz &amp; van der
  Laan (2018)](https://doi.org/10.1007/978-3-319-65304-4_14),
  [Díaz &amp; Hejazi (2020)](https://doi.org/10.1111/rssb.12362) ]

???

* _Stochastic interventions_ modify the value `\(S\)` would naturally assume by
  drawing from a modified exposure distribution.
* Consider post-intervention value `\(S^{\star} \sim G^{\star}(\cdot \mid L)\)`;
  static interventions are a special case (degenerate distribution).
* Such an intervention generates a counterfactual RV
  `\(Y_{G^{\star}} := f_Y(S^{\star}, L, U_Y)\)`, with distribution `\(P_0^{\delta}\)`.
* Estimate `\(\psi_{0,\delta} := \mathbb{E}_{P_0^{\delta}} \{Y_{G^{\star}}\}\)`,
  the counterfactual mean under post-intervention distribution `\(G^{\star}\)`.

---

## Quantifying SVE

* Causal parameter based on vaccine efficacy (VE) estimands:
  $$
    \text{SVE}(\delta) = 1 - \frac{\mathbb{E}[\mathbb{P}(Y = 1 \mid A = 1,
    S = s + \delta, L = l) \mid A = 1, L]}{\mathbb{P}(Y(0)=1)}
  $$
* `\(\mathbb{P}(Y(0)=1)\)`: counterfactual infection risk in the placebo arm.
  Under randomization, `\(\mathbb{P}(Y(0)=1) = \mathbb{P}(Y=1 \mid A=0)\)`.
* Summarizes VE thru stochastic interventions indexed by `\(\delta\)`.
* _Inverse probability weighted augmentation\*_ to correct for two-phase
  sampling bias.
* Open source `R` package\** at https://github.com/nhejazi/txshift

.footnote[[*] [Rose &amp; van der Laan
  (2011)](https://doi.org/10.2202/1557-4679.1217),
  [Hejazi et al. (2020)](https://doi.org/10.1111/biom.13375) ]

.footnote[[**] [Hejazi &amp; Benkeser (2020)](https://doi.org/10.21105/joss.02447)]

---

## SVE in COVID: Marker 1

&lt;img src="/home/nsh/git/conf_ser2021_txshift_covpn/slides_rmd/img/sieveConcept2.png" width="70%" style="display: block; margin: auto;" /&gt;

---

## SVE in COVID: Marker 2

&lt;img src="/home/nsh/git/conf_ser2021_txshift_covpn/slides_rmd/img/sieveConcept2.png" width="70%" style="display: block; margin: auto;" /&gt;

---

## Thank you!

__Amazing statisticians:__

.pull-left[.tiny[
__Leadership__
* Dean Follmann (NIAID)
* Yonghong Gao (BARDA)
* Peter Gilbert (FHCRC, UW)

__NIAID__
* Martha Nason
* Mike Fay
* Pretty much all of NIAID Biostatistics

__CoVPN__
* David Benkeser (Emory)
* Marco Carone (UW)
* Iván Díaz (Weill Cornell)
* Alex Luedtke (UW)
* ...many others!

]]

.pull-right[.tiny[
__Fred Hutch__
* Youyi Fong
* Holly Janes
* Michal Juraska
* Yunda Huang
* Ying Huang
* Ollivier Hyrien
* ...many others!

__OWS Company statisticians__
* Way too many to name!
]]
    </textarea>
<style data-target="print-only">@media screen {.remark-slide-container{display:block;}.remark-slide-scaler{box-shadow:none;}}</style>
<script src="https://remarkjs.com/downloads/remark-latest.min.js"></script>
<script>var slideshow = remark.create();
if (window.HTMLWidgets) slideshow.on('afterShowSlide', function (slide) {
  window.dispatchEvent(new Event('resize'));
});
(function(d) {
  var s = d.createElement("style"), r = d.querySelector(".remark-slide-scaler");
  if (!r) return;
  s.type = "text/css"; s.innerHTML = "@page {size: " + r.style.width + " " + r.style.height +"; }";
  d.head.appendChild(s);
})(document);

(function(d) {
  var el = d.getElementsByClassName("remark-slides-area");
  if (!el) return;
  var slide, slides = slideshow.getSlides(), els = el[0].children;
  for (var i = 1; i < slides.length; i++) {
    slide = slides[i];
    if (slide.properties.continued === "true" || slide.properties.count === "false") {
      els[i - 1].className += ' has-continuation';
    }
  }
  var s = d.createElement("style");
  s.type = "text/css"; s.innerHTML = "@media print { .has-continuation { display: none; } }";
  d.head.appendChild(s);
})(document);
// delete the temporary CSS (for displaying all slides initially) when the user
// starts to view slides
(function() {
  var deleted = false;
  slideshow.on('beforeShowSlide', function(slide) {
    if (deleted) return;
    var sheets = document.styleSheets, node;
    for (var i = 0; i < sheets.length; i++) {
      node = sheets[i].ownerNode;
      if (node.dataset["target"] !== "print-only") continue;
      node.parentNode.removeChild(node);
    }
    deleted = true;
  });
})();
(function() {
  "use strict"
  // Replace <script> tags in slides area to make them executable
  var scripts = document.querySelectorAll(
    '.remark-slides-area .remark-slide-container script'
  );
  if (!scripts.length) return;
  for (var i = 0; i < scripts.length; i++) {
    var s = document.createElement('script');
    var code = document.createTextNode(scripts[i].textContent);
    s.appendChild(code);
    var scriptAttrs = scripts[i].attributes;
    for (var j = 0; j < scriptAttrs.length; j++) {
      s.setAttribute(scriptAttrs[j].name, scriptAttrs[j].value);
    }
    scripts[i].parentElement.replaceChild(s, scripts[i]);
  }
})();
(function() {
  var links = document.getElementsByTagName('a');
  for (var i = 0; i < links.length; i++) {
    if (/^(https?:)?\/\//.test(links[i].getAttribute('href'))) {
      links[i].target = '_blank';
    }
  }
})();</script>

<script>
slideshow._releaseMath = function(el) {
  var i, text, code, codes = el.getElementsByTagName('code');
  for (i = 0; i < codes.length;) {
    code = codes[i];
    if (code.parentNode.tagName !== 'PRE' && code.childElementCount === 0) {
      text = code.textContent;
      if (/^\\\((.|\s)+\\\)$/.test(text) || /^\\\[(.|\s)+\\\]$/.test(text) ||
          /^\$\$(.|\s)+\$\$$/.test(text) ||
          /^\\begin\{([^}]+)\}(.|\s)+\\end\{[^}]+\}$/.test(text)) {
        code.outerHTML = code.innerHTML;  // remove <code></code>
        continue;
      }
    }
    i++;
  }
};
slideshow._releaseMath(document);
</script>
<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
(function () {
  var script = document.createElement('script');
  script.type = 'text/javascript';
  script.src  = 'https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-MML-AM_CHTML';
  if (location.protocol !== 'file:' && /^https?:/.test(script.src))
    script.src  = script.src.replace(/^https?:/, '');
  document.getElementsByTagName('head')[0].appendChild(script);
})();
</script>
  </body>
</html>
